Selumetinib: Selumetinib, a MEK1/MEK2 inhibitor approved for NF–1-associated plexiform neurofibromas, has demonstrated efficacy in both NF–1-associated and sporadic OPG. Here, NF1 is linked to plexiform neurofibroma.